诊断时CD70过表达预测滤泡性淋巴瘤复发并支持CD19-CD70双靶点CAR-T治疗
研究对统一治疗的滤泡性淋巴瘤(FL)患者(随访>11年)比较复发与未复发者的诊断时免疫微环境,转录组显示复发者炎症通路富集且CD70上调,多重免疫荧光证实肿瘤细胞及CD8⁺和CD4⁺TFH细胞CD70过表达与无进展生存期较差相关。功能研究显示CD70⁺肿瘤细胞增殖更强并诱导T细胞CD70表达,形成正反馈环。体外及FL异种移植模型中,CD19-CD70双靶点CAR-T较单靶点CAR-T显示更强细胞毒性和疾病控制,可清除脾和骨髓肿瘤。
要点
- 诊断时CD70过表达与FL患者无进展生存期较差相关。
- CD70⁺肿瘤细胞增殖更强并诱导T细胞CD70表达,形成正反馈环。
- CD19-CD70双靶点CAR-T在FL模型中优于单靶点CAR-T。
核心结论
- 诊断时CD70过表达可预测FL复发,并为CD19-CD70双靶点CAR-T临床开发提供临床前依据。
研究设计与样本
- 回顾性分析统一治疗的FL患者(随访>11年),比较复发与未复发者的诊断时免疫微环境。
- 进行转录组分析、多重免疫荧光、功能研究及体外和体内CAR-T实验。
主要发现
- 复发患者转录组显示炎症反应通路富集,包括细胞因子过表达和CD70上调。
- 多重免疫荧光证实诊断时肿瘤细胞及CD8⁺和CD4⁺TFH细胞CD70过表达,与无进展生存期较差相关。
- CD70⁺肿瘤细胞增殖更强并诱导T细胞CD70表达,提示正反馈环维持免疫激活。
- 双靶点CAR-T在体外对FL、DLBCL和MCL患者来源球体显示增强细胞毒性。
- FL异种移植模型中双靶点CAR-T较单靶点CAR-T疾病控制更优,清除脾和骨髓肿瘤。
临床怎么用
- 诊断时CD70过表达可能有助于识别高危FL患者。
- CD19-CD70双靶点CAR-T是高风险FL及其他B细胞非霍奇金淋巴瘤的潜在治疗策略。
局限性
- 研究为临床前阶段,CD19-CD70双靶点CAR-T的临床疗效和安全性尚未验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although first-line immunotherapy achieves remission in most patients with follicular lymphoma (FL), improved biomarkers and therapeutic strategies are required to identify and manage those who relapse. We investigated the immune microenvironment at diagnosis in uniformly treated FL patients with extended follow-up (>11 years), comparing relapsed and relapse-free cases. Transcriptomic profiling revealed enrichment of inflammatory response pathways in relapsed patients, including cytokine overexpression and upregulation of CD70, a molecule implicated in immune activation and inflammation. Multiplex immunofluorescence confirmed CD70 overexpression at diagnosis in tumor cells as well as in CD8⁺ and CD4⁺ T follicular helper (TFH) cells, correlating with inferior progression-free survival. Functional studies demonstrated that CD70⁺ tumor cells were more proliferative and induced CD70 expression in T cells, suggesting a feed-forward loop sustaining immune activation. To target these cells and enhance current CAR-T approaches, we engineered dual CD19-CD70 chimeric antigen receptor (CAR) T cells by co-transducing the CD19-CAR-T ARI-0001 with a CD27-based anti-CD70 CAR. Dual CAR-T cells exhibited enhanced in vitro cytotoxicity against patient-derived spheroids of FL, diffuse large B-cell lymphoma, and mantle cell lymphoma. In FL xenograft models, dual CAR-T treatment achieved superior disease control compared to monotargeted CAR-T cells, inducing complete tumor clearance in spleen and bone marrow. Collectively, these findings provide strong preclinical rationale for the clinical development of CD19-CD70 dual CAR-T therapy to improve outcomes in high-risk FL and potentially other B-cell non-Hodgkin lymphomas.
引用
- Araujo-Ayala F, Ros M, Alexandru R, et al. CD70 Overexpression at Diagnosis Predicts Relapse and supports dual CD19-CD70 CAR-T Therapy in Follicular Lymphoma. Blood. 2026. PMID: 42485767. doi:10.1182/blood.2025032663
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。